阿伏苯唑对Wistar大鼠的抗糖尿病活性

Antidiabetic Activity of Afobazole in Wistar Rats.

作者信息

Ostrovskaya R U, Ivanov S V, Voronin M V, Ozerova I V, Zolotov N N, Seredenin S B

机构信息

V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.

出版信息

Bull Exp Biol Med. 2018 Sep;165(5):649-652. doi: 10.1007/s10517-018-4233-4. Epub 2018 Sep 17.

DOI:10.1007/s10517-018-4233-4

PMID:30225697

Abstract

Using the streptozotocin model of type 2 diabetes mellitus in Wistar rats, we compared antidiabetic activity of anxiolytic Afobazole with that of metformin. Afobazole in a dose of 10 mg/kg reduced streptozotocin-induced hyperglycemia and polyphagia and prevented accumulation of malonic dialdehyde, being not inferior to metformin in a dose of 300 mg/kg, and was even more effective than metformin in body weight recovery, elimination of polydipsia, and preservation of these effects after treatment withdrawal.

摘要

利用链脲佐菌素诱导的Wistar大鼠2型糖尿病模型，我们比较了抗焦虑药物阿福唑嗪与二甲双胍的抗糖尿病活性。剂量为10mg/kg的阿福唑嗪可降低链脲佐菌素诱导的高血糖和多食，并防止丙二醛的积累，其效果不低于剂量为300mg/kg的二甲双胍，且在体重恢复、消除多饮以及停药后维持这些效果方面比二甲双胍更有效。